急性冠脉综合征患者血清白介素-6、C-反应蛋白浓度的变化及他汀类药物的干预治疗
出处
《中国煤炭工业医学杂志》
2006年第11期1199-1200,共2页
Chinese Journal of Coal Industry Medicine
参考文献10
-
1Ridker PM,Cushmanmm, Stampfer MJ. Plasma concentration of C- reactive protein and risk of developing peripheral vascalar disease[J]. Circalation, 1998,5 :425 - 428
-
2RajavashisthTB, Xu, Jovinges, et al. Membrcene type 1 mamx metal- loproteinase expression in human atheros cleroic plaques evidemce for altivation by proinfla mmatry mekiators[J]. Circulation, 1999,99:3103 - 3109
-
3Yesojima K, Schwabc, Edith G. Generation of C- reactive protein plaqus[J]. Am J Pathol,2001,158 : 1039 - 1051
-
4Andric R,Maylahn M,Braun P,et al. C- reactive proein in coronary plaqus prevalence with acute coronny syndrome[J]. Z Kardiol,2002,91 : 913 - 920
-
5Koenig W, Sund M, Frohlich M, et al. C - reactive protein, asensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middeaged men: Results from the MONICA Augsburg cohore study by 1984-1992[J]. Circulation, 1999,99 : 237 - 242
-
6Bickel C, Ruppreht HJ, Blankenbery S, et al. Relation of markrs of in- flannnation (C- reactive proein, fibrinogen, Von willebr and factor and leukocyte count) and statin therapy to longoterm mortality in patients with angiographically proven coronary artery disease[J]. Am J Cardid,2002,89 :901 - 908
-
7Ridker PM, Rifai N, Marc A, et al. Inflammatiin, pravastatin, and the risk of coronary evenes after mgocardial infarction in patients with average Cholesterol levels[J]. Circulation, 1998,98:839- 844
-
8Bustosc, Mernandrz presa MA, Ortego M, et al. HMG - COA reductase inhibition by atorvasatin reduces neointimal in flammation in a rabbitmodel of atheros clerosis[J]. J Am Cd 1 Cardid,1998,32:2057- 2064
-
9Aikawa M,Rabkin E,Sugiyama S,et al. An HMG- COA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metall oproteinases and tissue faltor in vivo and in vitro[J]. Circulation, 2001,103 : 276 - 283
-
10Rosenson RS, Tangney CC,caseylc,lnhibition of proinflam matory cytokine production by pravastatin [J]. Lancet, 1999,353:983- 984
-
1朱莹莹,皇晓娟.沙美特罗替卡松联合沙丁胺醇治疗慢性阻塞性肺疾病临床观察[J].解放军医药杂志,2016,28(1):93-95. 被引量：29
-
2杨孟选,可妮,刘保池.脓毒症患者血清白介素-6的表达及其意义[J].中国全科医学,2010,13(32):3600-3602. 被引量：13
-
3姜玲,范洁,丁立群,张翔,封淑青.阿托伐他汀在急性冠脉综合征患者抗炎中的应用效果观察[J].临床合理用药杂志,2013,6(9):61-61. 被引量：2
-
4梁一梅,梁一举,杨朝晖.前列腺素E_1在全身炎症反应综合征治疗中的应用[J].现代医药卫生,2006,22(2):162-163. 被引量：4
-
5王潭枫,陈文思,陈月燕.ITP患者血清白介素-6和肿瘤坏死因子-α的变化——附58例检测分析[J].新医学,2007,38(9):596-597.
-
6朱晓云,朱继金.辛伐他汀对急性冠脉综合征患者初期血浆IL-6和MMP-9的影响[J].广西医科大学学报,2007,24(6):906-908. 被引量：2
-
7乔广印,张红梅.血清白介素-6、白介素-8、肿瘤坏死因子在甲状腺机能减退时的改变[J].菏泽医学专科学校学报,2006,18(1):46-47. 被引量：1
-
8魏枫,王彩丽,王素华,徐燕,乔宏伟.血清白介素-6、白介素-8、肿瘤坏死因子在甲状腺功能减低状态下的变化[J].医师进修杂志,2004,27(11):28-29. 被引量：1
-
9米娜瓦.阿巴斯,祖木来提.吐尔逊,杨晓红.布地奈德对支气管哮喘患者血清炎性因子及免疫功能的影响[J].海南医学院学报,2015,21(8):1042-1044. 被引量：24
-
10谭洪文,何茜,徐淑静,杨天和,吴强.2型糖尿病并发冠心病患者血清白介素-6浓度的变化及意义[J].遵义医学院学报,2012,35(3):213-216. 被引量：3
